Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phil Skolnick

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Pharmacology & Therapeutics|October 12, 2021
Treatment of overdose in the synthetic opioid eraPhil Skolnick
European Journal of Pharmacology|August 10, 2018
On the front lines of the opioid epidemic: Rescue by naloxonePhil Skolnick
Annual Review of Pharmacology and Toxicology|October 3, 2017
The Opioid Epidemic: Crisis and SolutionsPhil Skolnick
The Journal of Clinical Psychiatry|September 30, 2004
Beyond monoamine-based therapies: clues to new approachesPhil Skolnick
Trends in Pharmacological Sciences|September 18, 2012
Anxioselective anxiolytics: on a quest for the Holy GrailPhil Skolnick
Trends in Pharmacological Sciences|October 6, 2015
Biologic Approaches to Treat Substance-Use DisordersPhil Skolnick
Journal of Neural Transmission (Vienna, Austria : 1996)|January 2, 2020
Cannabinoid<sub>1</sub> (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdosePhil Skolnick, Roger Crystal
Expert Opinion on Investigational Drugs|August 24, 2007
Triple uptake inhibitors: therapeutic potential in depression and beyondZhengming Chen, Phil Skolnick
Annals of the New York Academy of Sciences|December 20, 2003
Glutamate and depression: clinical and preclinical studiesIan A Paul, Phil Skolnick
CNS & Neurological Disorders Drug Targets|April 14, 2007
Triple reuptake inhibitors ("broad spectrum" antidepressants)Phil Skolnick, Anthony S Basile
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Pharmacology & Therapeutics|October 12, 2021
Treatment of overdose in the synthetic opioid eraPhil Skolnick
European Journal of Pharmacology|August 10, 2018
On the front lines of the opioid epidemic: Rescue by naloxonePhil Skolnick
Annual Review of Pharmacology and Toxicology|October 3, 2017
The Opioid Epidemic: Crisis and SolutionsPhil Skolnick
The Journal of Clinical Psychiatry|September 30, 2004
Beyond monoamine-based therapies: clues to new approachesPhil Skolnick
Trends in Pharmacological Sciences|September 18, 2012
Anxioselective anxiolytics: on a quest for the Holy GrailPhil Skolnick
Trends in Pharmacological Sciences|October 6, 2015
Biologic Approaches to Treat Substance-Use DisordersPhil Skolnick
Journal of Neural Transmission (Vienna, Austria : 1996)|January 2, 2020
Cannabinoid<sub>1</sub> (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdosePhil Skolnick, Roger Crystal
Expert Opinion on Investigational Drugs|August 24, 2007
Triple uptake inhibitors: therapeutic potential in depression and beyondZhengming Chen, Phil Skolnick
Annals of the New York Academy of Sciences|December 20, 2003
Glutamate and depression: clinical and preclinical studiesIan A Paul, Phil Skolnick
CNS & Neurological Disorders Drug Targets|April 14, 2007
Triple reuptake inhibitors ("broad spectrum" antidepressants)Phil Skolnick, Anthony S Basile
Pageof 6